MIR155HG

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, MIR155HG Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MIR155HG data layer compared with 24 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher MIR155HG Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MIR155HG expression acts as an unfavorable survival marker.

STAD are the cancer types where MIR155HG Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
STADDFSMedianII,III,IV0.1690.641.00715view →
Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

MIR155HG–STAD (DFS)

Kaplan–Meier survival curve for MIR155HG mutant vs wild-type samples in STAD.

Open the STAD breakdown →

Exploration